where science meets solutions
State-of-the-art manufacturing of pharmaceutical products, precise secondary packaging and quality-assured wholesale.
Product
Development
Modern pharmaceutical development from concept to market readiness – Complex Pharmaceuticals
Quality
management
Highest standards, precise processes and strict controls in accordance with all GxP requirements.
Packaging
know-how
Tailor-made packaging concepts for pharmaceutical products and clinical trials – Quality and precision at every stage.
Efficiency, precision, quality
Complex Pharmaceuticals specialises in the manufacture, secondary packaging, and wholesale of pharmaceutical products. The company follows a clear vision: To optimise the entire pharmaceutical value chain through innovative approaches. Efficiency, precision, and quality are always at the heart of the company’s culture.
Specialist in secondary packaging
With our specially designed secondary packaging, we can efficiently and precisely package commercial batches in standard sizes, as well as small and micro batches and clinical trial materials, all tailored to your requirements.
Pharmaceutical Manufacturer
As a pharmaceutical manufacturer, we facilitate the market introduction of approved pharmaceutical products and support clinical trials with customised packaging solutions, fully compliant with the highest regulatory standards
Research & Development
Thanks to our expertise and flexible processes, we offer pioneering solutions for a dynamic field.
Expertise
We support pharmaceutical companies in the EU, particularly in Austria, Germany, and Switzerland, with the safe and efficient supply
of their pharmaceutical products.
Pharmaceutical product manufacturing
Secondary production
Pharmaceutical wholesale
Regulatory expertise
Rare diseases – Orphan diseases
Rare diseases –
Orphan Diseases
Although rare diseases are not very widespread when considered individually, they occur frequently overall and can affect all organ systems. Those affected are among the most underserved patient groups worldwide.
In Austria, this affects one in 20 people – a total of around 500,000 people. In comparison, cardiovascular diseases affect around 300,000 Austrians. Despite the low number of cases, there are numerous established medicines and therapies available for these conditions – a supply-gap that has yet to be closed when it comes to rare diseases.
Orphan drugs only account for a small proportion of total drug expenditures. Due to the small patient population, the costs of the long-term development of an orphan drug must be recouped through a limited number of prescriptions. Consequently, the price of such a drug must be higher than that of a pharmaceutical product which is used by a large number of patients. No comprehensive figures are available for Austria, but in Germany, which is a comparable market, the gross cost share of orphan drug finished products covered by health insurance funds is only 5.4%.
News
Corporate news and trends from the world of pharmaceuticals
Podcasts
Key insights into sustainability, resilience and quality.
Büro
Complex Pharmaceuticals GmbH
Storchengasse 1
1150 Wien | Austria
Telefon
Bürozeiten
Mo bis Fr. 09:00 bis 18:00 Uhr
Tel: +43 1 208 01 34